Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 6
2005 2
2006 3
2007 4
2008 4
2009 4
2010 3
2011 6
2012 4
2013 8
2014 11
2015 12
2016 15
2017 12
2018 13
2019 15
2020 18
2021 19
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

147 results
Results by year
Filters applied: . Clear all
Page 1
NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E, Scaltriti M, Drilon A. Cocco E, et al. Among authors: scaltriti m. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Nat Rev Clin Oncol. 2018. PMID: 30333516 Free PMC article. Review.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. Hyman DM, et al. Among authors: scaltriti m. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Nature. 2018. PMID: 29420467 Free PMC article. Clinical Trial.
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. Razavi P, et al. Among authors: scaltriti m. Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008. Cancer Cell. 2018. PMID: 30205045 Free PMC article.
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Li BT, et al. Among authors: scaltriti m. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989854 Free PMC article. Clinical Trial.
Prevalence and role of HER2 mutations in cancer.
Cocco E, Lopez S, Santin AD, Scaltriti M. Cocco E, et al. Among authors: scaltriti m. Pharmacol Ther. 2019 Jul;199:188-196. doi: 10.1016/j.pharmthera.2019.03.010. Epub 2019 Apr 2. Pharmacol Ther. 2019. PMID: 30951733 Free PMC article. Review.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M, Baselga J. Vasan N, et al. Among authors: scaltriti m. Science. 2019 Nov 8;366(6466):714-723. doi: 10.1126/science.aaw9032. Science. 2019. PMID: 31699932 Free PMC article.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: scaltriti m. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S, Ferrando L, Cocco E, Ho SY, Tan DS, Sallaku M, Wu F, Acevedo B, Selenica P, Ross DS, Witkin M, Sawyers CL, Reis-Filho JS, Verma CS, Jauch R, Koche R, Baselga J, Razavi P, Toska E, Scaltriti M. Arruabarrena-Aristorena A, et al. Among authors: scaltriti m. Cancer Cell. 2020 Oct 12;38(4):534-550.e9. doi: 10.1016/j.ccell.2020.08.003. Epub 2020 Sep 3. Cancer Cell. 2020. PMID: 32888433 Free PMC article.
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, Zhao H, Wu F, Sallaku M, Qu X, Zhao A, Collings CK, D'Avino AR, Jhaveri K, Koche R, Levine RL, Reis-Filho JS, Kadoch C, Scaltriti M, Leslie CS, Baselga J, Toska E. Xu G, et al. Among authors: scaltriti m. Nat Genet. 2020 Feb;52(2):198-207. doi: 10.1038/s41588-019-0554-0. Epub 2020 Jan 13. Nat Genet. 2020. PMID: 31932695 Free PMC article.
147 results